High expression of ANXA11 was closely associated with adverse clinicopathological features, including larger tumor size, deeper invasion, lymph node metastasis, advanced TNM stage, and vascular invasion, suggesting a role in GC progression. This evidence concerns the gene ANXA11 and gastric cancer.